Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology248 enrolled

Overview

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies tissue samples from patients with non-small cell lung cancer.

OBJECTIVES: * To identify and characterize single nucleotide variations (SNVs) in non-small cell lung cancer (NSCLC) specimens. * To identify and characterize structural variations in the genomes of NSCLC specimens. * To identify and characterize other genomic alterations including, but not limited to, expression profiling and methylation. OUTLINE: DNA and RNA extracted from archived specimens are analyzed for single nucleotide variations, structural variations in the genomes, and other genomic alterations including, but not limited to, gene expression profiling and methylation. Clinical data related to disease, treatment, and recurrence from each patient sample is also collected.

Study Type

OBSERVATIONAL

Enrollment

248

Conditions

Lung Cancer

Interventions

DNA analysisGENETIC

DNA methylation analysisGENETIC

RNA analysisGENETIC

gene expression analysisGENETIC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Patient must have been registered to CALGB 140202. * Tumor histology should be either primary adenocarcinoma or squamous cell carcinoma of the lung. * Patients are eligible for this study if their samples from CALGB 140202 are available. * All living patients must sign the CALGB 151107 consent form to be eligible for this trial.

Locations (11)

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

Los Angeles, California, United States

Tunnell Cancer Center at Beebe Medical Center

Lewes, Delaware, United States

CCOP - Christiana Care Health Services

Newark, Delaware, United States

Outcomes

Primary Outcomes

Identification and characterization of SNVs in primary adenocarcinoma of the lung or squamous cell carcinoma of the lung

Time frame: up to 5 years

Identification and characterization of structural variations in the genomes of NSCLC

Time frame: up to 5 years

Identification and characterization of other genomic alterations including, but not limited to, gene expression profiling and methylation

Time frame: up to 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.